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Histone, and non-histone, protein acetylation plays an important role in a variety of cellular 
events, including the normal and abnormal development of blood cells, by changing 
the epigenetic status of chromatin and regulating non-histone protein function. Histone 
acetyltransferases (HATs), which are the enzymes responsible for histone and non-histone 
protein acetylation, contain p300/CBP, MYST, and GNAT family members. HATs are not 
only protein modifiers and epigenetic factors but also critical regulators of cell develop-
ment and carcinogenesis. Here, we will review the function of HATs such as p300/CBP, 
Tip60, MOZ/MORF, and GCN5/PCAF in normal hematopoiesis and the pathogenesis of 
hematological malignancies. The inhibitors that have been developed to target HATs will 
also be reviewed here. Understanding the roles of HATs in normal/malignant hematopoiesis 
will provide the potential therapeutic targets for the hematological malignancies.
Keywords: histone acetyltransferases, hematopoiesis, transcriptional regulation, hematopoietic stem cells, 
hematological malignancies
introduction
Histone acetyltransferases (HATs) acetylate histone proteins by transferring acetyl group from 
acetyl-CoA to specific lysine residues (1, 2). The acetylation of histones by HATs results in a 
dispersed structure of chromatin, which becomes accessible by transcriptional factors. Besides 
histones, a variety of non-histone substrates also have been shown to be acetylated by HATs, thus 
the HATs are now generally categorized as lysine acetyltransferases (3). The acetylome studies have 
led to discovery of many new substrates of HATs, and a lot of non-histone substrates of HATs, 
such as AML1, AML1-ETO (AE), p53, c-MYC, NF-κB, Cohesin and Tubulin, have been found 
to play important roles in different cellular processes (4–10). Based on the cellular localization, 
HATs are classified into type A and type B HATs. The type A HATs show nuclear localization and 
likely catalyze the processes related to transcription (11). The type A HATs are further divided 
into five families according to their homology and acetylation mechanisms. The GNAT family 
members include PCAF, Gnc5 and ELP3. CBP and p300 form the CBP/p300 family (12). Tip60, 
MOZ, MORF, HBO1 and HMOF belong to the MYST family (13). The transcriptional factor related 
HAT family includes TAF1 and TIFIIIC90. In addition, several steroid receptor co-activators, 
such as p600, SRC1, CLOCK and AIB1/ACTR/SCR3 etc., are also HATs. (14, 15). Type B HATs 
are localized in the cytoplasm and they are shown to acetylate the newly synthesized histones. For 
Table 2 | The role of HaTs in hematological malignancies.
acetyltransferase Disease Non-histone substrate Target genes established role/function inhibitors
p300/CBP AML C-Myb, AML1–ETO Id1, p21, Egr1 Block differentiation and promote self-renewal C646, EGCG, L002
p300 T cell leukemia Notch3 Unknown Promote Notch3-induced T cell proliferation Garcinol
Tip60 AML, lymphoma Unknown C-Myc, p53 Tumor suppressor and modulate DDR signaling Garcinol
MOZ/MORF AML AML1 p53, RARβ, PU.1 MOZ-related fusion proteins transduce HSPCs Garcinol
GCN5 B cell ALL, AML E2A-PBX1, AME Syk, Btk Promote cell transformation MB-3, Garcinol
PCAF AML, CML AME AML1 Promote AML1-dependent transcription MG153, Garcinol
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example, HAT1 is one of type B HAT members and functions 
in DNA repair and histone deposition (16).
Histone acetyltransferases play key roles in normal and malig-
nant hematopoiesis. The acetylation of histones and non-histone 
proteins has been shown to regulate normal blood cell develop-
ment (17–19) (Table 1). Analysis of chromatin factor interaction 
network in hematopoietic development shows multiple chromatin 
factor complexes, including NuA4/P300/CBP/HBO1, are required 
for normal hematopoiesis (20). Protein acetylation regulates 
hematopoietic stem cell (HSC) self-renewal, proliferation, and 
their differentiation into committed hematopoietic progenitors. 
In line with the critical functions of HATs in normal hematopoiesis, 
chromosomal translocations that involve HAT genes are frequently 
found in hematological malignancies. Recent cancer genome 
studies have identified HATs as common targets for mutations in 
these diseases. Meanwhile, the acetylation states of some onco-
proteins and tumor suppressor proteins have been correlated with 
hematological malignancies manifestation (5, 19, 21–25) (Table 2). 
Notably, most leukemogenic fusion proteins physically interact 
with HATs, even though they are not directly fused with HATs, 
suggesting that the aberrant acetylation regulation by these fusion 
proteins are critically important in leukemogenesis (26). In this 
article, we will first briefly review a few examples of interesting 
findings that potentially lead to development of new therapeutic 
strategies for hematological malignancies, and then provide an 
overview of the functions of HATs in normal and malignant 
hematopoiesis (Figure 1). 
Table 1 | The role of HaTs in hematopoietic stem/progenitor cells.
Cell type acetyl- 
transferase
Target  
genes
established role/
function
Hematopoietic 
stem/progenitor 
cells
p300 C-Myb Block proliferation and 
promote differentiation
CBP Gfi1b Promote self-renewal  
and block differentiation
MOZ p16 Generate and maintain 
HSCs
Myeloid 
progenitor cells
p300/CBP C-Myb Block proliferation and 
promote differentiation
MOZ p16 Promote hematopoietic 
progenitors proliferation
HBO1 Gata1 Promote fetal liver 
erythropoiesis
Lymphoid cells p300 Foxp3/C-Myb Regulate Foxp3(+) 
Treg cell function and 
homeostasis
GCN5 PI3K/AKT/Syk/Btk Regulate B cell apoptosis
bromodomains are Promising Targets for 
treating Hematological malignancies
Acetylated lysine residues generated by HATs can be specifically 
bound by some protein domains (“readers”). Bromodomains 
have been identified as an important type of the readers of acetyl 
lysine. The human genome encodes over 60 bromodomain 
proteins, including HATs, HAT-associated proteins (such as 
GCN5L2, PCAF, and BRD9), histone methyltransferases (such as 
ASH1L and MLL), transcriptional co-activators (such as TRIMs 
and TAFs), as well as the BET family proteins (27). BRD4, a 
member of the BET family proteins, is shown to locate at the 
enhancer and/or promoter regions of many active genes. The 
bromodomain inhibitor JQ1 is able to disassociate BRD4 from 
acetylated histones, leading to downregulation of gene transcrip-
tion and decreased phosphorylation of RNA polymerase II (28) 
(Figure 2). JQ1 is also able to remove BRD4 from the super-
enhancers and thus repress many super-enhancer regulated 
oncogenes. These findings have been verified in hematological 
malignancies, such as diffuse large B cell lymphoma (DLBCL), 
and provide a basis for using JQ1, as well as other BET bromodo-
main inhibitors, in the treatment of hematological malignancies 
(29–31).
HaTs Generate the Markers of Super-
enhancers in Hematological Malignancies
Super-enhancers are clusters of active enhancers bound by master 
transcription factors and cofactors, including the mediator complex, 
and can promote the high-level expression of genes that control 
cell identity (32, 33). Cancer cells can acquire super-enhancers to 
active oncogenes, which suggest that super-enhancer-associated 
genes could be candidate oncogenic drivers (29, 34–36). Histone 
H3 lysine 27 acetylation (H3K27ac) by p300/CBP is used as an 
active enhancer mark, which biophysically facilitates opening of 
chromatin and recruits the co-activators that recognize ϵ-acetyl 
lysine through bromodomain (37). BRD4 is most commonly asso-
ciated with enhancer regions, defined by the presence of H3K27ac 
by p300/CBP and the absence of H3K4me3. In a genome-wide 
study of DLBCL, a rank ordering of the enhancer regions by 
H3K27ac enrichment reveals that BRD4 binds to the majority of 
active enhancers and that the genome-wide correlation between 
BRD4 occupancy and H3K27ac is extremely strong. Importantly, 
BRD4 is highly loaded at the super-enhancers (29). These findings 
suggest that the HAT-mediated H3K27ac and the BRD4 recruit-
ment may play an important role in the formation and function 
of the super-enhancers.
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Histone acetylation-Methylation Crosstalk 
in Hematological Malignancies
Polycomb group (PcG) proteins are transcriptional repressors, 
and their abnormal expression is frequently associated with 
hematological malignancies. The PcG proteins can induce 
transcription repression through disassociating HATs from their 
target genes (38). The Polycomb repressive complex 2 (PRC2) 
catalyzes trimethylation of H3K27, and this activity is important 
for transcriptional repression. Depletion of PRC2 leads to a global 
increase of H3K27 acetylation, which is catalyzed by p300 and CBP. 
In MLL-AF9-transduced HSCs, the transcriptional activation of 
PcG-targeted genes has been found to correlate with a methylation-
to-acetylation change (Figure 1). These findings suggest that the 
acetylation–methylation crosstalk plays an important role in 
hematological malignancies.
FiGuRe 1 | Recent advances in the emerging fields of histone acetylation 
in hematopoiesis: (1) bromodomains are a promising target for the 
therapy of hematological malignancies; (2) HaTs generate histone marks 
found in active enhancers; (3) Histone acetylation-methylation crosstalk 
in hematopoiesis; (4) Third generation HDaC inhibitors for the therapy of 
hematological malignancies.
FiGuRe 2 | Histone acetyltransferases regulate both normal and malignant hematopoiesis.
The Role of Histone acetyltransferases in 
Normal Hematopoiesis
The Role of HaTs in Hematopoietic Stem/
Progenitor Cells
p300/CBP Knockout Mouse studies
The initial studies showed that CBP, instead of p300, is pivotal 
for the self-renewal of HSCs. However, it has been shown that 
p300, but not CBP, is essential for hematopoietic differentiation 
(39). However, it has been recently reported that CBP regulates 
both self-renewal and differentiation in adult HSCs and that loss 
of CBP leads to an increase in apoptosis, differentiation, and 
quiescence in HSCs through regulating Gfi1b (40). The num-
bers of colony-forming cells and erythroid cells are reduced in 
mouse embryos expressing the truncated CBP protein (1–1084 
amino acids), which suggests that CBP mutations disrupt 
May 2015 | Volume 5 | Article 1084
Sun et al. Histone acetyltransferases regulate hematopoiesis
Frontiers in Oncology | www.frontiersin.org
primitive hematopoiesis. Abnormal endothelial precursors have 
been found when the CBP mutant para-aortic splanchnopleural 
mesoderm was cultured with stromal cells, suggesting defects in 
the hematopoietic microenvironment (39). CBP+/− mice develop 
highly penetrant, multilineage defects in hematopoietic differ-
entiation (41). These findings indicate that CBP has important 
functions in normal hematopoiesis. No such pathology was 
observed in p300+/− mice. Thus, p300 and CBP play essential 
but distinct roles in maintaining normal hematopoiesis (42).
MOZ is Crucial for the Generation and Development of 
HSPCs
MOZ contains two coactivation domains and a HAT catalytic 
domain. The fetal liver cells with moz mutation were able to help 
reconstitute the hematopoietic system in the lethally irradiated 
recipient mice. In the Moz-deficient mice, the number of hemat-
opoietic progenitors in all lineages was reduced, and defects 
in HSCs were found (43). Loss of MOZ HAT activity causes 
abnormalities in hematopoietic stem/progenitor cell (HSPC) 
numbers in mice since HSPCs lacking MOZ HAT activity cannot 
expand. Loss of MOZ HAT activity also leads to the disruption of 
B cell development in mice. MOZ-mediated acetylation has been 
found to play an important role, controlling the balance between 
differentiation and proliferation in normal hematopoiesis (26, 
44). MOZ controls the proliferation of HSCs at least in part 
by repressing the transcription of p16. The expression level of 
p16 is increased in HSPCs without MOZ HAT activity, which 
can induce the senescence of HSPCs. Loss of p16 rescues the 
proliferative abnormality in the hematopoietic progenitors 
lacking the MOZ HAT activity. These findings indicate an 
important role of MOZ HAT activity in the transcription of 
p16 and HSPC senescence (45). Together, MOZ is essential 
for a fundamental property of HSCs and the development of 
hematopoietic progenitors.
The Role of HaTs in Myeloid Progenitors and 
Differentiation
The KIX Domains of p300/CBP are Required for Definitive 
Hematopoiesis
The KIX domains in p300 and CBP are responsible for inter-
acting with other proteins, and they regulate c-Myb-mediated 
transcription activation and repression. Loss of the CH1 
or KIX domain in p300 leads to profound abnormalities in 
hematopoiesis, while deletion of other portions of p300 only 
affects some specific lineages (46). Certain site specific point 
mutations in the KIX domain of p300 can disrupt the interaction 
between p300 and CREB/c-Myb, and mice homozygous for these 
mutations have many hematopoietic defects, such as anemia, 
thrombocytosis, megakaryocytosis, thymic hypoplasia, and B 
cell deficiency. However, no defects are detected in mice carrying 
the same point mutations in CBP. The interaction between the 
KIX domain of p300 and c-Myb is important for the function 
and development of megakaryocytes, and a synergistic genetic 
interaction has been found between the mutations in the KIX 
domain of p300 and mutations in c-Myb. CBP KIX domain 
mutations affect platelets, B cells, T cells, and red cells. Therefore, 
the KIX domains in p300 and CBP have their unique functions 
in normal hematopoiesis (47). Altogether, the KIX domains 
in p300 and CBP are essential for the normal hematopoiesis 
through regulating c-Myb-mediated transcription activation 
and repression (48).
The Hbo1-Brd1/Brpf2 Complex is Required for Fetal Liver 
Erythropoiesis
HBO1 is responsible for the acetylation of histone H4K5, K8, 
and K12. The interaction between ING4 and histone H3K4me3 
augments the ability of HBO1 to acetylate histone H3 (49, 
50). HBO1 and BRD1 can form a HAT complex and control 
erythropoiesis. Loss of Brd1 leads to severe anemia in mouse 
embryos due to abnormal erythropoiesis in the fetal liver. HBO1 
and BRD1 are found to mostly co-localize in the erythroblast 
genome, and regulate critical developmental genes. Loss of 
Brd1 or depletion of Hbo1 significantly decreases the levels 
of H3K14 acetylation in erythroblasts. Loss of Brd1 leads to 
reduced expression of Gata1, the key erythroid developmental 
regulator, and the forced expression of Gata1 can partially rescue 
the abnormal erythropoiesis induced by loss of Brd1. Taken 
together, the Brd1–Hbo1 HAT complex is an important H3K14 
HAT, which is essential for the transcriptional activation of key 
erythroid regulators (17).
The Role of HaTs in lymphoid Cells
p300 is Critical for the Function and Homeostasis of 
Foxp3(+) Treg Cells
Forkhead box P3 (Foxp3) is acetylated by p300 and is essen-
tial for the development of a Treg suppressor phenotype. 
Hyperacetylation of Foxp3 prevents its ubiquitination and 
proteasome mediated degradation, which leads to a significant 
increase in the Foxp3 protein level. Foxp3 acetylation can rapidly 
control Foxp3 protein levels in T cells, which provides a new 
mechanism for regulating the number and function of Treg cells 
(51). In the presence of a p300 inhibitor, Garcinol, p300 becomes 
disassociated from the FOXP3 protein complex, and subse-
quently FOXP3 is degraded through the lysosome-dependent 
system. A subset of four lysine residues, which together control 
the total acetylation of FOXP3, could also be acetylated by p300 
(52, 53). The conditional deletion or pharmacologic inhibition 
of p300, was able to increase apoptosis induced by the T cell 
receptor in Foxp3(+) Treg cells, and inhibit tumor growth in 
immunodeficient mice. Together, p300 is critical for the func-
tion and homeostasis of Foxp3(+) Treg cells, and thus p300 
inhibitors are able to impair the function of Treg cells without 
affecting T effector cells suggesting a new approach for cancer 
immunotherapy (54).
The Role of GCN5 in Lymphoid Cells
GCN5 controls the PI3K/AKT pathway activation through regulat-
ing the transcription of Btk and Syk, which are involved in PI3K/
AKT pathway activation in B cells under oxidative stress. GCN5 
deficiency significantly induced apoptosis in chicken DT40 cells 
treated with hydrogen peroxide. GCN5 is localized at the proximal 
5′-upstream regions of Btk and Syk, and the expression levels of Syk 
and Btk were significantly decreased in GCN5-deficient chicken 
DT40 cells exposed to exogenous hydrogen peroxide. Moreover, 
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the phosphorylation level of AKT was also significantly decreased 
in hydrogen peroxide-treated GCN5-deficient chicken DT40 cells. 
Together, GCN5 regulates the transcription of Btk and Syk, and 
is crucial for the epigenetic regulation of the PI3K/AKT pathway 
activation in lymphoid cells under oxidative stress (55).
The Role of Histone acetyltransferases in 
Malignant Hematopoiesis
p300/CbP
The Interaction of p300/CBP with c-Myb is Required for 
the Induction of Acute Myeloid Leukemia
CBP/p300 is an essential co-activator for the transforming capacity 
of c-Myb (56). CBP/p300 is required for the ability of c-Myb to 
repress several key target genes involved in myeloid differentiation 
and p300 is recruited to c-Myb-binding sites close to c-Myb target 
genes (57). The interaction of p300/CBP with c-Myb is essential 
for leukemic transformation by the myeloid leukemia oncogenes 
AE, MLL-ENL, and MLL-AF9 (58). The p300–c-Myb interaction 
is essential for the ability of AE, MLL-ENL, and MLL-AF9 fusion 
proteins to confer self-renewal properties on myeloid progenitor 
cells. In the absence of this interaction, these fusion oncoproteins 
are unable to impose a block of differentiation, leading instead 
to terminal differentiation. Myeloid progenitors from Plt6 mice, 
which have a mutation in p300, are also refractory to transfor-
mation by the AE and MLL fusion proteins. Taken together, the 
specific interaction between p300 and c-Myb is required to control 
a transcriptional program, which is essential for the acquisition 
of self-renewal and possibly other leukemogenic properties upon 
expression of fusion oncoproteins. Thus, disruption of the p300–c-
Myb interaction could be a potential therapeutic strategy for acute 
myeloid leukemia (AML) (58).
The Acetylation of Notch 3 by p300 in T Cell Leukemia
Notch3 is acetylated at lysine 1692 and lysine 1731 by p300, which 
can be deacetylated by HDAC1. The acetylation of Notch3 by p300 
is able to promote its ubiquitination and protein degradation 
through proteasome system. Consequently, the expression level 
of Notch3 and its transcriptional activity are decreased in the non-
acetylatable Notch3 mutant transgenic mice, which leads to defects 
in the Notch3 downstream signaling. The non-acetylatable Notch3 
mutant can enhance Notch3-induced growth of T cell leukemia 
proliferation, which can be blocked by a histone deacetylases 
(HDAC) inhibitor. In the Notch3 transgenic mouse model, 
HDAC inhibitor-mediated hyperacetylation of Notch3 inhibits 
the proliferation of T cell leukemia/lymphoma cells. Altogether, 
targeting Notch3 deacetylation could be a promising therapeutic 
strategy for T-cell leukemia (25).
The HAT Domain and Bromodomain are Required for 
MLL–CBP-Induced Transformation in AML
The CBP gene is fused with the MLL gene in patients with 
t(11;16) MDS; the MLL–CBP fusion contains a mostly intact 
CBP, suggesting involvement of CBP in leukemogenesis (59). 
Both the CBP HAT domain and bromodomain are required for 
MLL–CBP-induced transformation in AML, which is usually 
preceded by an MDS phase. The replacement of the MLL–CBP 
HAT domain with the PCAF/GCN5 HAT domain enhanced the 
proliferation of hematopoietic progenitor cells and led to the loss 
of myeloid cell surface markers in these cells. These phenotypes 
were not observed when the CBP bomodomain of MLL–CBP was 
replaced by the PCAF/TAFII250 bromodomain. The recipient 
mice transplanted with domain-swapped hematopoietic pro-
genitors developed lymphoid disease or had low-frequency 
MDS that progressed to AML. Thus, the CBP HAT domain and 
bromodomain have different functions but play important roles 
in the pathogenesis of MLL–CBP-positive leukemias (60).
The Acetylation of the AE Fusion Protein by p300 is 
Required for the Induction of Acute Leukemia
We have shown that transcriptional activation by AE is crucial 
for leukemogenesis and that AE interacts with the transcriptional 
co-activator, p300. The important function of the AML1–ETO/
p300 interaction is that AE can be acetylated, as acetylation of AE 
is essential for its self-renewal promoting effects. The acetylation 
of AE9a by p300 at a specific lysine residue (K43) is required for 
its ability to induce leukemia in mice. Pharmacological and RNA 
interference-mediated inhibition of p300 specifically impairs AE/
AE9a-induced transcriptional activation and leukemogenesis, 
but does not affect the development of MLL–AF9-induced 
leukemia. Acetyl-AEK43 is present in blast cells isolated from 
t(8;21) leukemia patients and these leukemia cells, but not normal 
human CD34+ cells, are sensitive to growth inhibition by p300 
inhibitors. AE and p300 co-localize at the regulatory regions 
of many AE upregulated genes, which includes the regulators 
of self-renewal (e.g., Id1, p21, and Egr1). AE and p300 can 
cooperate in the transcriptional regulation of these target genes. 
Several TFIID subunits that specifically bind to a K43 acetylated 
AML1 peptide but not to the identical non-acetylated peptide. 
Furthermore, these results establish a novel link between post-
translational modification of a non-histone protein (by a “histone 
modifying enzyme”) and transcriptional regulation, which has 
crucial implications for the study of cancer and the regulation 
of gene expression. As ETO is thought to be a key component 
of co-repressor complexes, its interactions with the co-activator 
p300 in cells is surprising and raises a question about whether 
“bipotential” complexes, like bivalent histone marks, may allow 
cells to turn on or off a given set of genes in response to certain 
internal or external signals. Thus, acetylation of an oncogenic 
fusion transcription factor itself can promote gene activation 
independent of any effect on histone acetylation, and can be 
essential for leukemia stem cell to self-renewal and malignant 
transformation (4, 61).
Tip60
Tip60 is Required for an Oncogene-Induced DNA-
Damage Response
Tip60 regulates several transcription factors, which can promote 
or suppress carcinogenesis (e.g., p53 and Myc). Tip60 regulates 
DNA-damage response (DDR) signaling induced by oncogenes, 
which can prevent cancer progression. Loss of one allele of Tip60 
inhibited Myc-induced DDR but had no effect on DDR in normal 
B cells. In the Tip60 heterozygous knockout mice, Tip60 inhibits 
Myc-induced lymphomagenesis at the pre-tumoral stage. The 
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mono-allelic loss of Tip60 occurs often in lymphomas with con-
comitant reduction in mRNA levels; this often coexists with p53 
mutations and is related to the disease grade. Thus, Tip60 functions 
as a tumor suppressor in a haplo-insufficient manner, and Tip60 
is essential for controlling Myc-induced DDR in cancer cells (62).
Tip60 is Involved in c-Myb-Driven Leukemogenesis
TIP60 interacts with c-Myb, which requires the transactivation 
domain of c-Myb and the HAT domain of TIP60. Coexpression of 
TIP60 impairs c-Myb-induced transcription activation. TIP60 can 
bind to the promoters of c-Myb target genes, which is dependent on 
c-Myb. Furthermore, c-Myb interacts with HDAC1 and HDAC2, 
which are associated with TIP60 and cause transcriptional repres-
sion. TIP60 negatively regulates the transcription activity of c-Myb 
through interacting with HDACs in human hematopoietic cells. 
Consistently, knockdown of Tip60 increased the expression level of 
c-Myc. It has been found that the expression level of Tip60 is much 
(~60%) lower in the patients with AML. These findings suggest 
that TIP60 regulates the function of c-Myb and that dysregulated 
TIP60 could be involved in c-Myb-driven leukemogenesis (63).
MOZ/MORF
The MOZ-TIF2 Fusion Protein is Associated with AML
MOZ–TIF2 is associated with AML chromosomal abnormalities at 
inv(8)(p11q13). MOZ–TIF2 contains the CBP interaction domain 
(CID) of TIF2 and the HAT domains of MOZ and TIF2 (64–67). 
In a murine bone marrow transplant assay, MOZ–TIF2 causes 
AML that could be serially transplanted (67). It has been found 
that the interaction between MOZ–TIF2 and CBP through the 
CID domain and the C2HC nucleosome recognition motif in MOZ 
are essential for transformation (68). MOZ–TIF2 dominantly 
inhibits the transcription activity of CBP-dependent activation 
(e.g., p53 and nuclear receptors), which requires the CID domain. 
The nuclear localization of MOZ–TIF2 is abnormal, which 
is dependent on the MOZ portion of this fusion protein. CBP 
expression is decreased in the cells expressing MOZ–TIF2, which 
results in the depletion of CBP from PML bodies. The critical 
characteristics of MOZ–TIF2 are to disrupt the normal activity 
of CBP/CBP-dependent activators in acute myeloid leukemia 
(69). MOZ–TIF2 binds to the promoter of RARβ2, leading to 
the dissociation of CBP/p300, the abnormal histone acetylation 
and the downregulation of RARβ2. MOZ–TIF2 was recruited to 
AML1 target promoters and upregulated transcription mediated 
by AML1. Both MOZ and MOZ–TIF2 were found to co-localize 
with AML1 (70). MOZ–TIF2 impaired retinoic acid-mediated 
transcription activation of C/EBPβ/CD11b, and inhibited nuclear 
receptor-induced gene activation through aberrant recruitment 
of CBP, which required both the MOZ and TIF2 domains of this 
fusion protein (71).
In a transgenic zebrafish model, spi1 promoter-driven 
MOZ–TIF2 expression induced the development of AML in 2 
of 180 embryos expressing MYST3/NCOA2, in which kidney 
invasion by myeloid blast cells was observed (72). MOZ–TIF2 
interacted with PU.1 to stimulate the expression of M-CSFR, and 
PU.1 is required for the establishment and maintenance of LSCs 
by MOZ–TIF2. Loss of CSF1R impairs MOZ–TIF2-induced 
leuekmogenesis in mouse models and CSF1R inhibitors delay 
the development of MOZ–TIF2-induced AML (73). MOZ–TIF2 
can cooperate with FLT3–ITD to transform hematopoietic 
cells. STAT5 signaling is required for MOZ–TIF2-induced 
leukemogenesis. Deletion of STAT5 led to the differentiation 
of MOZ–TIF2-transduced fetal liver cells, and these cells lost 
their replating ability. The recipient mice transplanted with 
Stat5−/− MOZ–TIF2 leukemia cells have longer latency and 
incomplete penetrance. STAT5 is essential for the self-renewal 
of leukemia stem cells in MOZ–TIF2 driven leukemia (74). 
Overexpression of HOXA9, HOXA10, and MEIS1 was observed 
in AML patients with MOZ fusions. MOZ–TIF2 forms a stable 
complex with bromodomain-PHD finger protein 1 (BRPF1), 
and MOZ–TIF2/BRPF1 associate with Hox genes in the 
MOZ–TIF2 driven leukemia cells. BRPF1 depletion disrupts 
the localization of MOZ on the Hox genes, which led to the 
inhibition of MOZ–TIF2-induced transformation. Moreover, 
mutant MOZ–TIF2 lacking HAT activity could not deregulate 
HOX genes or initiate AML. Thus, MOZ–TIF2/BRPF1 induces 
leukemogenesis through the upregulation of HOX genes, which 
is regulated by MOZ-dependent histone acetylation (75).
MOZ–CBP and MOZ–p300 are Generated by 
Chromosomal Translocations in AML
The recurrent translocation t(8;16)(p11;p13) leads to the 
MOZ–CBP fusion gene, which contains the MOZ finger motifs 
and HAT domain and a mostly intact CBP (76). This t(8;16)
(p11;p13) translocation occurs in the M5 subtype AML, which 
is characterized by erythrophagocytosis and a poor prognosis. 
The CBP–MOZ mRNA is not in-frame, which suggested that 
MOZ–CBP is the critical fusion for the initiation of leukemia 
(77, 78). MOZ, CBP, and MOZ–CBP are all able to acetylate the 
transcription factor AML1. The level of MOZ–AML1 complex 
upregulates when M1 myeloid cells differentiate into mac-
rophages/monocytes. This finding suggests that the MOZ–AML1 
complex could have important functions in the differentiation 
of myeloid cells. MOZ–CBP inhibits the differentiation of M1 
myeloid cells, and could induce the development of leukemia 
through impairing AML1-induced transcription activation (79). 
MOZ–CBP cooperates with steroid receptor co-activator-1 to 
activate transcription, and the CBP portion of MOZ–CBP is 
required for the transcription activity of this fusion protein. It 
has been found that the interaction between MOZ–CBP and 
NF-κB could also have critical functions in leukemogenesis 
(80). MOZ–CBP inhibits p53-mediated transcription, and the 
impairment of MOZ/p53-induced transcription contributes to 
the development of leukemia (81).
The translocation t(8;22)(p11;q13) in acute myeloid leukemia 
generates the fusion gene MOZ–p300, and the MOZ zinc finger/
HAT domain are fused to a mostly intact p300. Thus, MOZ–p300 
has two HAT domains from MOZ and p300 portions, and may 
play an important role in the development of leukemia through 
deregulation of histone acetylation (82). It has been found 
that MOZ is fused with an unknown partner at 2p23 in one 
patient with tMDS. Therefore, MOZ might lead to the abnormal 
histone acetylation and promote the pathogenesis of myeloid 
malignancies (83).
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GCN5/PCaF
The t(1;19) translocation was found in pediatric pre-B cell ALL, 
which leads to the fusion of E2A and PBX1 and the generation 
of a E2A–PBX1 fusion protein. E2A–PBX1 is able to induce the 
transformation of hematopoietic cells. It has been found that 
SPT3–TAFII31–GCN5L acetylase (STAGA) and its HAT subunit 
GCN5 directly binds to the E2A portion of E2A–PBX1. GCN5 
can acetylate and stabilize the E2A–PBX1 fusion protein (23). 
AML1/MDS1/EVI1 (AME), a transcription repressor generated 
by translocation t(3;21) in human leukemia, binds to P/CAF 
and GCN5 through two binding sites, with one of the binding 
sites being in the Runt domain. GCN5 and P/CAF are able to 
acetylate AME, and either P/CAF or GCN5 can cooperate with 
AME to impair the repression of AML1-dependent transcriptional 
activation (84, 85).
The important Role of p53 acetylation in 
Hematological Malignancies
The transcription factor p53 was the first non-histone substrate 
discovered to be acetylated by HATs (5). Levels of p53 acetyla-
tion are associated with the activation and stabilization of p53 
(86–93); acetylation of p53 also stimulates its sequence-specific 
DNA-binding (94–97). The seven different lysine (K164, K305, 
K370, K372, K373, K381, and K382) in the C-terminus of p53 are 
acetylated by CBP and PCAF (98). Acetylation of p53 is crucial for 
the recruitment of CBP/p300 to the promoters of its target genes. 
CBP and p300 are able to promote p53-mediated transcription 
activation (99). TIP60/hMOF acetylates p53 at position 120 (100, 
101), which can be induced by DNA damage or oncogenic stress-
mediated p19ARF activation (102). Mutation of p53 lysine 120 
to arginine inhibited p53-induced transcription activation. p53 
can also be acetylated at one lysine outside its C-terminus, which 
is critical for the activation of the proapoptotic genes PUMA 
and BAX. In the p53 acetylation-deficient knockin mouse, the 
expression of p53 target genes is decreased after DNA damage 
(103). The deletion of the lysine residue at position 164 and other 
acetylation sites in p53 blocked p53-mediated transactivation of 
p21 and inhibition of cell growth (104). These findings suggest 
that p53 acetylation may play a critical role in the pathogenesis 
of hematological malignancies.
Third Generation HDaC inhibitors for the 
Therapy of Hematological Malignancies
The FDA approved drug, Beleodaq, is used for the therapy of 
patients with peripheral T cell lymphomas (PTCL), an aggres-
sive disease, which accounts for ~15% of all non-Hodgkin 
lymphomas. Beleodaq inhibits HDAC and it is the third drug to 
receive FDA approval for PTCL. In the trial that led to the FDA 
approval, Beleodaq’s overall response rates were comparable to 
those of Folotyn and Istodax; 10.8% of patients experienced a 
complete response and 15% had a partial response. The response 
rate was even higher in patients with angioimmunoblastic T 
cell lymphoma, which suggests that targeting acetylation is a 
promising therapeutic strategy for the therapy of hematological 
malignancies.
The Potential Therapeutic effects of Histone 
acetyltransferase inhibitor in Hematopoiesis
The HaT inhibitor, Garcinol, induces the expansion 
of Hematopoietic Stem/Progenitor Cells
The HAT inhibitor, Garcinol, is derived from plants. It has 
been identified as a stimulator of human HSPCs expansion in 
the screening of natural products. During a 7-day culture of 
CD34+CD38− HSCs or CD34+ HSPCs, Garcinol was able to induce 
the expansion of HSPCs, and this ability is associated with its 
inhibitory effect on HATs. The derivatives of Garcinol, which can 
expand HSPCs, are also able to inhibit HAT activity and histone 
acetylation. Altogether, the Garcinol effects suggest that targeting 
HATs could be a promising strategy for expanding HSPCs (105).
inhibition of p300 impairs antitumor immunity
Foxp3+ Treg cells can not only regulate immune homeostasis/
autoimmunity but also limit the immune response of hosts to 
tumors. Thus, targeting Foxp3+ Treg cells could be a promising 
strategy to improve antitumor immunity. Conditional deletion 
or pharmacological inhibition of p300 was able to increase T cell 
receptor-induced apoptosis in Foxp3+ Treg cells and abrogate 
the suppressive functions of Treg cells. Inhibition of p300 can 
also impair the induction of peripheral Treg cells and tumor 
growth in the immunocompetent mouse model. Collectively, 
p300 is critical for the homeostasis and function of Foxp3+ Treg 
cells, and targeting p300 could be a new approach for cancer 
immunotherapy (54).
The p300 inhibitor, C646, acts selectively on 
t(8;21) leukemia Cells
The HAT p300 can enhance the self-renewal ability of leukemia 
stem cells through acetylating AE and activating the target genes 
of AE, which indicated that p300 could be a promising drug target 
for t(8;21) leukemia. C646, a selective and competitive p300 inhibi-
tor, can inhibit the proliferation and colony formation of t(8;21) 
leukemia cells, and induce apoptosis and G1 phase cell cycle arrest 
in t(8;21) leukemia cells and primary cells isolated from patients 
with t(8;21) leukemia. C646 does not significantly affect the normal 
HSPCs mobilized by GCSF. In particular, AML1−ETO+ AML cells 
are more sensitive to C646 compared with AML1−ETO− AML cells. 
The growth inhibition of AML1−ETO+ leukemia cells induced by 
C646 are associated with the decreased acetylation of histone H3 
and downregulation of Bcl2/C-kit, suggesting that C646 could 
be a promising drug candidate for the treatment of AML1−ETO+ 
leukemia (4, 106).
The HaT inhibitor, epigallocatechin-3-Gallate, 
inhibits b cell Transformation
Epigallocatechin-3-gallate (EGCG) has been found as a HAT 
inhibitor in natural compound screening. EGCG can block 
p300-mediated acetylation of p65, impairing its translocation 
to the nucleus, and it can upregulate the amount of IκBα in the 
cytoplasm, thus inhibiting NF-κB activity in several ways, and 
decreasing the expression of NF-κB target genes. EGCG impairs 
B cell transformation by EBV, perhaps via suppression of NF-κB 
acetylation (107), and it can inhibit the binding of p300 to the IL-6 
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promoter and block cytokine gene expression. Thus, EGCG could 
be a potential therapy for B cell malignancies.
leukemia and lymphoma Cell lines are 
sensitive to p300 inhibitor l002
p300 plays an important role in signal transduction pathways that 
promote the proliferation and survival of malignant cells. Therefore, 
p300 represents a promising drug target for hematological malig-
nancies, and libraries of compounds have been screened for p300 
inhibitors. One candidate, L002, inhibits p300 in vitro, with an IC50 
of ~2 μM. L002 can block histone acetylation and p53 acetylation, 
and can inhibit the activation of STAT3. Biochemical testing of a 
series of related compounds revealed functional groups that may 
impact the inhibitory potency of L002 against p300. Interestingly, 
these analogs show inhibitory activities against CBP, PCAF, and 
GCN5, but against several other acetyltransferases (KAT5, KAT6B, 
and KAT7), HDACs and HMTases. Among the NCI-60 panel of 
cancer cell lines, leukemia, and lymphoma cell lines were extremely 
sensitive to L002. Thus, this new acetyltransferase inhibitor, L002, 
is a potential anticancer agent (108).
anacardic acid Derivatives inhibit PCaF and 
induce apoptosis in Chronic Myeloid  
leukemia Cells
The different acetylation of proteins correlates with the develop-
ment of BCR–ABL-positive leukemia. A derivative of anacardic 
acid – small molecule MG153, which is developed to have stronger 
HAT inhibitory ability, is a potent inhibitor of PCAF. The inhibition 
of PCAF decreases proliferation and induces apoptosis, which 
correlates with loss of the mitochondrial membrane potential 
and DNA fragmentation. Importantly, cells expressing BCR–ABL 
are more sensitive to PCAF inhibition compared to parental cells 
without BCR–ABL. Moreover, inhibition of PCAF in BCR–ABL-
expressing cells breaks their resistance to DNA damage-induced 
cell death. Targeting the PCAF alone or in combination with DNA-
damaging drugs shows cytotoxic effects and should be considered 
as a prospective therapeutic strategy in chronic myeloid leukemia 
(CML) cells. Moreover, anacardic acid derivative MG153 is a valu-
able agent and further studies validating its therapeutic relevance 
should be performed (109).
GCN5 inhibitors have anti-leukemia effects
The a-methylene-g-butyrolactone 3 (MB-3) is a cell-permeable 
inhibitor against GCN5, and is able to decrease the levels of 
histone H3 acetylation and non-histone substrate (a-tubulin) 
acetylation. GCN5 acetylates E2A–PBX1, and MB-3 reduces the 
levels of E2A–PBX1 acetylation and E2A–PBX1 protein in a 
dose-dependent manner. RCH–ACV cells are derived from the 
bone marrow cells of a patient with pre-B cell acute lymphoid 
leukemia, and has t(1;19) translocation, which generates the 
E2A–PBX1 fusion gene. E2A–PBX1 acetylation was inhibited 
by MB-3, and the level of E2A–PBX1 and GCN5 protein was 
decreased when RCH–ACV cells were treated with MB-3. The 
E2A–PBX1 half-life was shorter in the cells treated with MB-3, 
indicating GCN5-dependent acetylation can affect the stability 
of E2A–PBX1 protein. A reduction in Wnt16, an E2A–PBX1 
target gene were also observed in RCH–ACV cells cultured 
with MB-3, indicating the importance for the pathogenesis of 
t(1;19)-positive pre-B cell leukemia. Additionally, the expression 
of E2A–PBX1, E2A, and Wnt16 were significantly decreased 
in the primary t(1;19) pre-B ALL cells treated with MB-3. 
MB-3 does not affect the expression of Pol II or Tubulin, which 
suggests that MB-3 can destabilize certain proteins probably 
through the inhibition of GCN5-dependent histone or non-
histone substrate acetylation. These findings indicate that 
GCN5 inhibitors have potential value as therapeutic agents 
for ALL (23). Some recently identified GCN5 inhibitors, such 
as (thiazol-2-yl)hydrizones (110, 111), might also be able to 
target hematological malignancies.
Conclusions
Lysine acetylation acetylation occurs not only at the histone tails 
but also in the non-histone proteins. LATs are catalytic subunits 
of multiprotein complexes, whose biochemical and molecular 
characterization have yielded much important information 
about the function and regulation of acetyltransferase activity. 
Importantly, HATs have the catalytic/non-catalytic and histone/
non-histone effects on the hematopoietic cells, which confer HAT 
the ability to control a variety of cellular events in normal and 
malignant hematopoiesis. Genetic approaches are very useful to 
study how protein acetylation controls a variety of cellular events 
in normal and malignant hematopoiesis. The study on the gene 
knockout mouse models shows that p300 and CBP play distinct 
roles in hematopoiesis; GCN5 but not PCAF is essential in early 
embryonic development. Thus, such an in vivo approach will gen-
erate the new findings on the role and mechanism of LATs. One 
major finding in the mechanism study on the function of protein 
acetylation is that bromodomain can bind to the acetylated lysine. 
Since a lot of proteins have bromodomain, it would be interest-
ing to understand whether all bromodomains can recognize the 
acetylated lysine and how bromodomains specifically recognize 
the acetylated lysine. MOZ, MORF, p300, and CBP are involved 
in the leukemia-associated chromosomal translocation, which 
can generate leukemogenic fusion genes. Thus, LATs have critical 
functions in the pathogenesis of hematological malignancies. 
The direct involvement of LATs in hematological malignancies 
indicates that compounds with the ability to regulate the activity 
of LATs are the potential drugs for the treatment of hematological 
malignancies. Thus, the studies on the function and mechanism 
of histone/non-histone proteins acetylation will not only shed 
new light on how lysine acetylation controls a variety of cellular 
events in normal and malignant hematopoiesis but also provide 
critical insights into the development of new therapeutic strate-
gies for the therapy of hematological malignancies.
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